Sam Chun Dang Pharm secures exclusive contract for Eylea biosimilar in Europe, raises funds for global clinical trials through share placement, and starts generic ophthalmic product exports to US.
What is covered in the Full Insight:
Introduction
Geographic Expansion of Eylea Biosimilar
Share Placement for Clinical Trials
Ophthalmology Drug Export to US
Conclusion
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.